Opportunity Information: Apply for PA 18 773
Apply for PA 18 773
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "International Research Collaboration on Drug Abuse and Addiction Research (R01 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279.
- This funding opportunity was created on 2018-05-09.
- Applicants must submit their applications by 2021-05-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The International Research Collaboration on Drug Abuse and Addiction Research (R01 Clinical Trial Optional) opportunity (Funding Opportunity Number PA 18 773) is a National Institutes of Health grant announcement led by the National Institute on Drug Abuse (NIDA) that is designed to support research partnerships between U.S.-based investigators and collaborators located in other countries. The central idea is to fund drug abuse and addiction research that genuinely benefits from being conducted, at least in part, outside the United States because the international setting provides something that is difficult or impossible to replicate domestically. That could mean access to specialized scientific expertise, unique laboratories or technologies, distinctive datasets, particular public health infrastructures, specific policy or environmental contexts, or populations and patterns of substance use that would allow researchers to answer important questions faster or more convincingly than they could within the U.S. alone.
A key requirement is that proposed projects must do more than simply take place internationally; they must clearly explain why the non-U.S. location creates an unusual or special advantage that accelerates scientific discovery. Applicants are expected to connect those international advantages to concrete outcomes for the United States by showing how the work will significantly advance U.S. health sciences. In practice, this means making a strong case that the findings, methods, interventions, or data generated abroad will translate back to U.S. needs, inform U.S. prevention or treatment strategies, improve understanding of addiction mechanisms relevant to Americans, strengthen U.S. research capacity, or otherwise deliver clear value to U.S. public health.
The research must also be explicitly aligned with NIDA's mission and objectives, with the FOA pointing applicants to the NIDA Strategic Plan as a guide for demonstrating fit. Where feasible, NIDA encourages applicants to address its international scientific priority areas, signaling that NIDA is particularly interested in global research topics that complement and extend its broader addiction science agenda. This focus on alignment is not just a formality; the proposal should make it easy for reviewers to see that the aims are substance-use related, scientifically compelling, and tied to NIDA priorities rather than being a general global health project with only a minor addiction component.
On the collaboration side, the FOA requires a true partnership that includes at least one investigator from a U.S. institution and at least one non-U.S. citizen collaborator who is living and working in another country. This requirement is meant to ensure that the project is not merely U.S.-directed work conducted abroad, but instead a collaborative effort that leverages on-the-ground expertise and infrastructure in the partner country. Although the announcement does not spell out a specific collaboration model in the provided text, competitive applications typically make roles, responsibilities, and contributions of each partner clear, especially how the international partner enables the project to access resources or populations that are not otherwise available.
The award mechanism is an R01 research project grant, and the announcement is labeled "Clinical Trial Optional," meaning applicants may propose studies that include a clinical trial, but a clinical trial is not required. This allows a wide range of project types, from basic and translational research through epidemiology, prevention, implementation science, services research, and potentially intervention testing, as long as the work remains focused on drug abuse and addiction and meets the collaboration and international advantage criteria.
Eligibility is broad and includes many types of U.S. and non-U.S. organizations. Eligible applicants listed include state, county, city or township governments, special district governments, independent school districts, public and state-controlled institutions of higher education, private institutions of higher education, federally recognized Native American tribal governments, other Native American tribal organizations, public housing authorities/Indian housing authorities, nonprofits (both 501(c)(3) and non-501(c)(3)), for-profit organizations (other than small businesses), small businesses, and other entities. The FOA also explicitly notes additional eligible applicant categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, and non-domestic entities (foreign organizations), as well as regional organizations. The Catalog of Federal Domestic Assistance (CFDA) number associated with this opportunity is 93.279, and the funding activity category is listed under education and health.
Administrative details in the provided source indicate the FOA was created on 2018-05-09 and shows an original closing date of 2021-05-07, which is relevant for historical context but should be verified against current NIH/NIDA posting status if someone is looking to apply now, since NIH announcements can be reissued, expired, or replaced by updated FOAs over time. The source data does not specify an award ceiling or the expected number of awards, suggesting applicants would need to consult the full FOA text or NIH guidance for budget and programmatic expectations.
Overall, this grant opportunity is best understood as funding for internationally grounded addiction research that cannot be done as effectively within the United States, but that still has clear and substantial payoff for U.S. science and public health. Success hinges on demonstrating (1) a compelling addiction-related scientific question, (2) a strong rationale for the international setting as a unique accelerator of discovery, (3) clear relevance to NIDA priorities, and (4) a well-defined partnership between U.S. and non-U.S. investigators with meaningful contributions on both sides.
Frequently Asked Questions (FAQs)
What is the International Research Collaboration on Drug Abuse and Addiction Research (R01 Clinical Trial Optional) opportunity?
It is a National Institutes of Health (NIH) funding opportunity led by the National Institute on Drug Abuse (NIDA) to support international research partnerships focused on drug abuse and addiction research. The award mechanism is an R01 research project grant, and the opportunity is identified as Funding Opportunity Number (FON) PA 18 773.
Who leads this funding opportunity?
NIDA (the National Institute on Drug Abuse), which is part of NIH, leads this grant announcement.
What is the main purpose of this FOA?
The purpose is to fund drug abuse and addiction research projects that genuinely benefit from being conducted at least in part outside the United States, because the international setting provides a unique advantage that is difficult or impossible to replicate in the U.S.
Does the project have to take place outside the United States?
The central concept is that the research must be conducted, at least in part, outside the U.S. in a way that provides a special or unusual advantage for the science.
Is it enough to simply run a study in another country?
No. A key requirement is that the application must clearly explain why the non-U.S. location creates a special advantage that accelerates scientific discovery, rather than simply being an international site.
What kinds of "international advantages" does NIDA expect applicants to justify?
The FOA emphasizes advantages such as access to specialized scientific expertise, unique laboratories or technologies, distinctive datasets, particular public health infrastructures, specific policy or environmental contexts, or unique populations and patterns of substance use that would allow researchers to answer important questions faster or more convincingly than they could within the U.S. alone.
How should applicants connect international work to benefits for the United States?
Applicants are expected to show concrete outcomes for the U.S. by explaining how findings, methods, interventions, or data generated abroad will translate back to U.S. needs, advance U.S. health sciences, inform U.S. prevention or treatment strategies, improve understanding of addiction mechanisms relevant to Americans, strengthen U.S. research capacity, or otherwise deliver clear value to U.S. public health.
What research areas are eligible under this FOA?
Projects must be focused on drug abuse and addiction research and aligned with NIDA's mission and objectives. The FOA points applicants to the NIDA Strategic Plan as a guide for demonstrating fit.
Does NIDA have specific international priority areas?
Yes. Where feasible, NIDA encourages applicants to address its international scientific priority areas, indicating an interest in global research topics that complement and extend its broader addiction science agenda.
What does "Clinical Trial Optional" mean for this opportunity?
It means applicants may propose research that includes a clinical trial, but a clinical trial is not required. This allows a broad range of study types as long as they remain focused on drug abuse and addiction and meet the international collaboration and international-advantage expectations.
What types of studies might fit under this R01 (based on the FOA description provided)?
The FOA description indicates the opportunity can support a wide range of project types, including basic research, translational research, epidemiology, prevention research, implementation science, services research, and potentially intervention testing, as long as the project aligns with NIDA priorities and meets the collaboration and international setting rationale requirements.
What collaboration structure is required?
The FOA requires a true partnership that includes at least one investigator from a U.S. institution and at least one non-U.S. citizen collaborator who is living and working in another country.
Why does the FOA require an international collaborator who is a non-U.S. citizen living and working abroad?
This requirement is intended to ensure the project is not simply U.S.-directed work conducted abroad, but a collaborative effort that leverages on-the-ground expertise and infrastructure in the partner country.
Does the FOA describe a specific model for how the collaboration must be organized?
The provided information does not spell out a specific collaboration model. However, it notes that competitive applications typically make the roles, responsibilities, and contributions of each partner clear, especially how the international partner enables access to resources or populations not otherwise available.
What is the award mechanism for this announcement?
The award mechanism is an R01 research project grant.
Who is eligible to apply?
Eligibility is broad and includes many U.S. and non-U.S. organizations. Examples listed include state/county/city/township governments, special district governments, independent school districts, public and state-controlled institutions of higher education, private institutions of higher education, federally recognized Native American tribal governments, other Native American tribal organizations, public housing authorities/Indian housing authorities, nonprofits (501(c)(3) and non-501(c)(3)), for-profit organizations (other than small businesses), small businesses, and other entities.
Are minority-serving institutions and community-based organizations eligible?
Yes. The FOA explicitly notes additional eligible applicant categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), and faith-based or community-based organizations.
Are foreign organizations eligible to apply?
Yes. The eligibility list explicitly includes non-domestic entities (foreign organizations), as well as regional organizations.
Are U.S. territories or possessions included in eligibility?
Yes. The FOA explicitly includes U.S. territories or possessions among eligible applicant categories.
Are federal agencies eligible to apply?
Yes. The FOA explicitly notes eligible federal agencies as an eligible applicant category.
What is the CFDA number for this funding opportunity?
The Catalog of Federal Domestic Assistance (CFDA) number associated with this opportunity is 93.279.
What is the funding activity category listed for this opportunity?
The funding activity category is listed under education and health.
When was this FOA created, and what closing date is shown in the provided information?
The administrative details provided indicate the FOA was created on 2018-05-09 and shows an original closing date of 2021-05-07.
Is this opportunity still open based on the information provided?
The provided information shows an original closing date of 2021-05-07 and notes this is relevant for historical context. It also cautions that current status should be verified because NIH announcements can be reissued, expired, or replaced over time.
Does the provided information include an award ceiling or expected number of awards?
No. The provided source does not specify an award ceiling or the expected number of awards, and suggests applicants would need to consult the full FOA text or NIH guidance for budget and programmatic expectations.
How can applicants demonstrate strong alignment with NIDA priorities?
The FOA emphasizes that the research must be explicitly aligned with NIDA's mission and objectives and points applicants to the NIDA Strategic Plan as a guide for demonstrating fit. It also notes that alignment should be clear to reviewers, with substance-use-related aims that are scientifically compelling and tied to NIDA priorities (not a general global health project with only a minor addiction component).
What are the key elements reviewers are likely looking for based on the FOA description provided?
The description highlights that success hinges on (1) a compelling addiction-related scientific question, (2) a strong rationale for the international setting as a unique accelerator of discovery, (3) clear relevance to NIDA priorities, and (4) a well-defined partnership between U.S. and non-U.S. investigators with meaningful contributions on both sides.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education, Health
Next opportunity: Patient Safety in the Context of Perinatal, Neonatal, and Pediatric Care (R03 - Clinical Trial Optional)
Previous opportunity: Innovative Therapies and Tools for Screenable Disorders (R21 Clinical Trial Optional)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 18 773
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 18 773) also looked into and applied for these:
| Funding Opportunity |
|---|
| Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R21 Clinical Trial Not Allowed) Apply for RFA CA 18 014 Funding Number: RFA CA 18 014 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Investigation of the Transmission of Kaposi Sarcoma-associated Herpesvirus (KSHV)(R01 Clinical Trial Optional) Apply for RFA CA 18 013 Funding Number: RFA CA 18 013 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Precision Imaging of Oral Lesions (R01- Clinical Trial Not Allowed) Apply for PAR 18 787 Funding Number: PAR 18 787 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Genetic analysis of non-human animal models to understand the genomic architecture of substance use disorders and addictive behaviors (U01 Clinical Trial Not Allowed) Apply for PAR 18 789 Funding Number: PAR 18 789 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Computational Approaches to Curation at Scale for Biomedical Research Assets (R01 Clinical Trial Not Allowed) Apply for PAR 18 796 Funding Number: PAR 18 796 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R41/R42 - Clinical Trial Optional) Apply for PAR 18 802 Funding Number: PAR 18 802 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R43/R44 - Clinical Trial Optional) Apply for PAR 18 801 Funding Number: PAR 18 801 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Administrative Supplements to Promote Diversity in Small Businesses-SBIR/STTR (Admin Supp Clinical Trial Not Allowed) Apply for PA 18 837 Funding Number: PA 18 837 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Collaborative Human Tissue Network (CHTN) (UM1 Clinical Trials Not Allowed) Apply for RFA CA 18 025 Funding Number: RFA CA 18 025 Agency: National Institutes of Health Category: Education, Health Funding Amount: $800,000 |
| Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional) Apply for PA 18 842 Funding Number: PA 18 842 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24 - Clinical Trial Optional) Apply for PAR 18 841 Funding Number: PAR 18 841 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01 - Clinical Trial Optional) Apply for PAR 18 847 Funding Number: PAR 18 847 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R21 - Clinical Trial Optional) Apply for PAR 18 848 Funding Number: PAR 18 848 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional) Apply for PA 18 849 Funding Number: PA 18 849 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Prevention Research in Mid-Life Adults (R21 Clinical Trial Optional) Apply for PA 18 850 Funding Number: PA 18 850 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Administrative Supplements to Promote Collaborative Activities in Basic Cancer Research (Admin Supp - Clinical Trial Not Allowed) Apply for PA 18 852 Funding Number: PA 18 852 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention (R01 - Clinical Trial Optional) Apply for PA 18 863 Funding Number: PA 18 863 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention (R03 - Clinical Trial Optional) Apply for PA 18 861 Funding Number: PA 18 861 Agency: National Institutes of Health Category: Education, Health Funding Amount: $50,000 |
| Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention (R21 - Clinical Trial Optional) Apply for PA 18 862 Funding Number: PA 18 862 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) Apply for PAR 18 869 Funding Number: PAR 18 869 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 18 773", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.